Acute-on-chronic liver failure in chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 662-669

  Seto, Wai Kay ^a   Lai, Ching Lung ^a,b   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acute on chronic liver failure; Hepatitis B; Hepatitis B virus DNA; Liver failure; Model of End stage Liver Disease; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIBIOTIC AGENT; BILIRUBIN; CORTICOSTEROID; DEXAMETHASONE; ENTECAVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B(E) ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 17; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TENOFOVIR; TERLIPRESSIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG POTENCY; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; LONG TERM CARE; META ANALYSIS (TOPIC); MORTALITY; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH17 CELL; THROMBOCYTE COUNT; TREATMENT DURATION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 84858805271     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06971.x     Document Type: Review

References (82)

1. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 138-43.
2. Lai CL, Yuen MF. Chronic hepatitis B-new goals, new treatment. N. Engl. J. Med. 2008; 359: 2488-91.
3. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
4. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
5. Yuen MF, Seto WK, Chow DH etal. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295-303.
6. World Health Organization. WHO Fact Sheet N*204. Published August 2008. Cited 16 April 2011. Available from URL:
7. Sarin S, Kumar A, Almeida J etal. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol. Int. 2009; 3: 269-82.
8. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-97.
9. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann. Intern. Med. 2007; 147: 58-61.
10. Andreani T, Serfaty L, Mohand D etal. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin. Gastroenterol. Hepatol. 2007; 5: 636-41.
11. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89: 732-5.
12. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-43.
13. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-15.
14. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J. Hepatol. 1990; 10: 29-34.
15. Yuen M-F, Sablon E, Hui C-K etal. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin. Infect. Dis. 2003; 36: 979-84.
16. Yuen MF, Tanaka Y, Shinkai N etal. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57: 98-102.
17. Yuen M-F, Sablon E, Wong DK-H etal. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin. Infect. Dis. 2003; 37: 593-7.
18. Imamura T, Yokosuka O, Kurihara T etal. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut 2003; 52: 1630-7.
19. Yuen MF, Sablon E, Yuan HJ etal. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37: 562-7.
20. Yuen MF, Wong DK, Zheng BJ etal. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J. Viral Hepat. 2007; 14: 269-75.
21. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-56.
22. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N. Engl. J. Med. 1991; 324: 1699-704.
23. Yuen MF, Sablon E, Yuan HJ etal. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J. Infect. Dis. 2002; 186: 1335-8.
24. Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-8.
25. Kusumoto K, Yatsuhashi H, Nakao R etal. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J. Gastroenterol. Hepatol. 2008; 23: 790-3.
26. Lai CL, Yuen MF. Systemic corticosteroid and reactivation of chronic hepatitis B. Respirology 2010; 15: 1017-18.
27. Kim TW, Kim MN, Kwon JW etal. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology 2010; 15: 1092-7.
28. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
29. Yeo W, Chan TC, Leung NW etal. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009; 27: 605-11.
30. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination. Am. J. Med. 2005; 118: 21-7.
31. Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J. Gastroenterol. Hepatol. 2008; 23: 883-7.
32. Zhang X, Ke W, Xie J, Zhao Z, Xie D, Gao Z. Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B. Hepatol. Int. 2010; 4: 615-20.
33. Kumar Acharya S, Kumar Sharma P, Singh R etal. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J. Hepatol. 2007; 46: 387-94.
34. Kumar A, Das K, Sharma P, Mehta V, Sharma B, Sarin S. Hemodynamic studies in acute-on-chronic liver failure. Dig. Dis. Sci. 2009; 54: 869-78.
35. Yuen M-F, Ip P, Ng W-K, Lai C-L. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J. Hepatol. 2004; 41: 686-7.
36. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol. Res. 2009; 39: 427-31.
37. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver Dis. 2009; 29: 337-47.
38. Maini MK, Boni C, Lee CK etal. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 2000; 191: 1269-80.
39. Wasmuth HE, Kunz D, Yagmur E etal. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J. Hepatol. 2005; 42: 195-201.
40. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010; 11: 373-84.
41. Chen Z, Cheng Y, Xu Y etal. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin. Immunol. 2008; 128: 400-8.
42. Wang K, Liu H, He Y etal. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum. Immunol. 2010; 71: 950-6.
43. Zhang J-Y, Zhang Z, Lin F etal. Interleukin-17-producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
44. Wang K, Fan YC, Ge J etal. Elevated CPG island methylation of IL-17 promoter in acute-on-chronic hepatitis B liver failure [abstract]. J. Hepatol. 2011; 54 (Suppl.): S158.
45. Lemmers A, Moreno C, Gustot T etal. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49: 646-57.
46. Farci P, Diaz G, Chen Z etal. B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 8766-71.
47. Liu HG, Chen WW, Fan ZP etal. The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin. Immunol. 2007; 125: 337-45.
48. Gao L, Wang J-F, Xiang M, Fan Y-C, Zhang Z-G, Wang K. Expression of human glucocorticoid receptor in T lymphocytes in acute-on-chronic hepatitis B liver failure. Dig. Dis. Sci. 2011; 56: 2605-12.
49. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-9.
50. Cardenas A, Gines P. Acute-on-chronic liver failure: the kidneys. Curr. Opin. Crit. Care 2011; 17: 184-9.
51. Liu H, Lee SS. Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr. Opin. Crit. Care 2011; 17: 190-4.
52. Garcia-Martinez R, Cordoba J. Acute-on-chronic liver failure: the brain. Curr. Opin. Crit. Care 2011; 17: 177-83.
53. Sun QF, Ding JG, Xu DZ etal. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J. Viral Hepat. 2009; 16: 464-70.
54. Cui Y-L, Yan F, Wang Y-B etal. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig. Dis. Sci. 2010; 55: 2373-80.
55. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J. Hepatol. 2003; 38: 322-7.
56. Tsubota A, Arase Y, Suzuki Y etal. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J. Gastroenterol. Hepatol. 2005; 20: 426-32.
57. Wiesner R, Edwards E, Freeman R etal. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
58. Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am. J. Gastroenterol. 2006; 101: 1516-23.
59. Yu JW, Sun LJ, Zhao YH, Li SC. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J. Gastroenterol. Hepatol. 2008; 23: 1242-9.
60. Lee WC, Chou HS, Wu TJ, Lee CS, Lee CF, Chan KM. Indicators and outcome of liver transplantation in acute liver decompensation after flares of hepatitis B. J. Viral Hepat. 2011; 18: 193-9.
61. Kim WR, Biggins SW, Kremers WK etal. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 2008; 359: 1018-26.
62. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140: 1952-60.
63. Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl. 2007; 13: 1228-35.
64. Zheng MH, Shi KQ, Fan YC etal. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin. Gastroenterol. Hepatol. 2011; 9: 351-6.
65. Sanyal AJ, Boyer T, Garcia-Tsao G etal. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
66. Garg V, Kumar A, Garg HK, Sharma B, Trehanpati N, Sarin SK. Granulocyte-colony stimulating factor (G-CSF) therapy improves survival in patients with acute-on-chronic liver failure (ACLF)-a randomized placebo controlled trial [abstract]. Hepatology 2010; 52: 333A.
67. Hassanein TI, Schade RR, Hepburn IS. Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr. Opin. Crit. Care 2011; 17: 195-203.
68. Rifai K, Kribben A, Gerken G etal. A prospective randomized controlled multicenter study of extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS study) [abstract]. Hepatology 2010; 52: 333A.
69. Matsumoto K, Miyake Y, Miyatake H etal. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J. Gastroenterol. 2009; 15: 1650-2.
70. Zhang XQ, Jiang L, You JP etal. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol. Res. 2011; 41: 46-53.
71. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J. Gastroenterol. Hepatol. 2010; 25: 583-90.
72. Wong VW, Wong GL, Yiu KK etal. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J. Hepatol. 2011; 54: 236-42.
73. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774-80.
74. Wong VW, Wong GL, Tsang SW etal. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir. Ther. 2008; 13: 571-9.
75. Tillmann HL, Hadem J, Leifeld L etal. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J. Viral Hepat. 2006; 13: 256-63.
76. Lange CM, Bojunga J, Hofmann WP etal. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
77. Liaw YF, Sheen IS, Lee CM etal. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
78. Chan A, Fan S, Lo C etal. Liver transplantation for acute-on-chronic liver failure. Hepatol. Int. 2009; 3: 571-81.
79. Lo CM, Cheung ST, Lai CL etal. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann. Surg. 2001; 233: 276-81.
80. Naoumov NV, Lopes AR, Burra P etal. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J. Hepatol. 2001; 34: 888-94.
81. Buti M, Mas A, Prieto M etal. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol. 2003; 38: 811-17.
82. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.